Diamedica Therapeutics Inc. (DMAC) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 protein, for the treatment of Acute Ischemic Stroke (AIS) and Preeclampsia (PE). The company has no commercial product revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5.1) million | $(10.3) million | $(9.7) million |
| Net Loss Per Share | $(0.13) | $(0.27) | $(0.36) |
| Operating Cash Flow | N/A | $(11.2) million | $(10.1) million |
| Cash & Marketable Securities | $54.1 million (as of June 30, 2024) | $54.1 million | $52.9 million (Dec 31, 2023) |
| Working Capital | $51.9 million | $51.9 million | $50.9 million |
| Debt | Minimal (Lease obligations only) | ~$0.4 million total lease liabilities | ~$0.3 million total lease liabilities |
Material Changes vs. Prior Period
- Financing Activity: In June 2024, the company completed a private placement of 4.72 million shares, raising $11.7 million in net proceeds. This significantly bolstered cash reserves compared to the prior year.
- Expense Trends:
- R&D Expenses: Increased to $7.6 million for the six months ended June 30, 2024, from $6.2 million in the prior year period. This reflects continued costs for the ReMEDy2 trial and expanded clinical team staffing.
- G&A Expenses: Decreased to $3.8 million (YTD 2024) from $4.1 million (YTD 2023), driven by lower insurance premiums and legal fees, partially offset by increased personnel and share-based compensation costs.
- Other Income: Increased to $1.1 million (YTD 2024) from $0.5 million (YTD 2023) due to higher interest income on marketable securities.
Outlook, Risks, and Management Commentary
- Clinical Pipeline:
- AIS (ReMEDy2 Trial): The Phase 2/3 trial is ongoing but faces slower-than-expected site activations and enrollment due to staffing shortages and logistical challenges. The company is expanding the trial globally (Canada, Australia, Europe) to mitigate these delays.
- PE Expansion: Announced plans for a Phase 2 proof-of-concept trial for Preeclampsia in South Africa. First subject enrollment is anticipated in Q4 2024, with results expected in H1 2025. Estimated cost is $1.5 million.
- Liquidity: Management expects current cash resources ($54.1 million) to fund operations, the ReMEDy2 trial, and the new PE trial for at least the next 12 months. However, substantial additional capital will be required for future development and commercialization.
- Legal Proceedings: The company is involved in litigation with ICON/PRA Netherlands regarding clinical study data. While the company won ownership of the data in a lower court, a damages claim was rejected due to insufficient causal link. Both parties have appealed, with a consolidated hearing scheduled for March 2025.
- Risks: Key risks include the adaptive design of the ReMEDy2 trial, potential delays in enrollment, the success of the new PE trial, and the need for future equity financing which may dilute shareholders.
Investor Verification Checklist
- Verify the current enrollment rate and site activation status of the ReMEDy2 trial to assess timeline risks.
- Monitor the regulatory approval status and initiation timeline for the new Preeclampsia (PE) Phase 2 trial in South Africa.
- Track the status of the litigation appeal against ICON/PRA Netherlands scheduled for March 2025.
- Assess the company's cash burn rate relative to the $54.1 million cash balance to confirm the 12-month runway estimate.
- Review upcoming equity dilution risks given the company's reliance on private placements for funding.